Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)
2022-502057-33-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2 trial of SAR445514 in multiple myeloma (MM) and light-chain amyloidosis, sponsored by Sanofi. Started Jun 2023; status: completed.
02
Drugs
SAR445514
03
Conditions
multiple myeloma (MM)light-chain amyloidosis
Beyond the preview
Go deeper on 2022-502057-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502057-33-00.